Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.75 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.59 |
| ▸ | FAP | Q12884 | 3/20 | 0.59 |
| ▸ | PREP | P48147 | 3/20 | 0.59 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769136 | 1.00 | DPP4 (0.75) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2369832 | 0.89 | DPP4 (0.60) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2369828 | 0.89 | DPP4 (0.60) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7312802 | 0.87 | DPP4 (0.73) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL9840411 | 0.87 | DPP4 (0.73) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7312806 | 0.87 | DPP4 (0.73) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7021069 | 0.85 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7403443 | 0.85 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2196155 | 0.85 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19743784 | 0.85 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| CN-102302781-A | Medical use of inhibitors of glutaminyl and glutamate cyclases | PROBIODRUG AG | 2012-01-04 | — | — | CN | claimed |
| CN-1784220-B | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG | 2011-08-03 | — | — | CN | claimed |
| CN-101837127-A | The application of glutaminyl and glutamate cyclase effector | PROBIODRUG AG | 2010-09-22 | — | — | CN | claimed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | claimed |
| US-20090054519-A1 | DERIVATIVES OF MONOSACCHARIDES AS 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | claimed |
| EP-1915160-A2 | DERIVATIVES OF MONOSACCHARIDES FOR THE TREATMENT OF COPD AND ALLERGIC RHINITIS | Ranbaxy Laboratories Limited (IN) | 2008-04-30 | — | — | EP | claimed |
| EP-0842196-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1144425-B1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LAB LTD (IN) | 2004-06-16 | — | — | EP | claimed |
| US-6596687-B1 | For treatment of many inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-07-22 | — | — | US | claimed |
| CN-1343212-A | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2002-04-03 | — | — | CN | claimed |
| US-6329344-B1 | UREA DERIVATIVE OF ALKYLENE DIOXYFURAN ETHERS | RANBAXY LABORATORIES LIMITED (IN) | 2001-12-11 | — | — | US | claimed |
| EP-1144425-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2001-10-17 | — | — | EP | claimed |
| EP-0896538-B1 | USE OF ACTIVITY INHIBITING DIPEPTIDYL PEPTIDASE IV EFFECTORS FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS | PROBIODRUG GES FUER ARZNEIM (DE) | 2001-07-04 | — | — | EP | claimed |
| US-6239108-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2001-05-29 | — | — | US | claimed |
| WO-2000042053-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2000-07-20 | — | — | WO | claimed |
| WO-1997003094-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-01-30 | — | — | WO | claimed |
| US-4215047-A | FLUOROGENIC SUBSTRATES FOR DETERMINING ENZYMATIC ACTIVITIES | AJINOMOTO COMPANY INCORPORATED (JP) | 1980-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054519-A1 | DERIVATIVES OF MONOSACCHARIDES AS 5-LIPOXYGENASE INHIBITORS | ALOX5, ALOX15, ALOX15B | DPP4 973/4885DPP7 930/4885DPP8 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.